BURZYNSKI RESEARCH INSTITUTE INC (BZYR) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US1231591058

Price
0.00 USD
Market cap
26,289.69 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

BURZYNSKI RESEARCH INSTITUTE INC financials

Fiscal year2025
Revenue0.00 USD
Operating income-1.39 m USD
EBIT-1.39 m USD
Net income-1.39 m USD
Diluted EPS – continuing operations-0.01 USD

Full history since 1998, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BURZYNSKI RESEARCH INSTITUTE INC

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.